http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Guardant Health (GH) submits premarket approval application to the U.S. Food and Drug Administration for Shield blood test
-
Guardant Health submits premarket approval application to the U.S. Food and Drug Administration for Shield™ blood test
-
Guardant Health (GH) Appoints Musa Tariq to its Board
-
Musa Tariq Joins Guardant Health Board of Directors
-
Guardant Health to Participate in Upcoming March Investor Conferences
-
Guardant Health Initiates New Study to Examine the Impact of Shield™ Blood Test to Increase Screening Compliance for Colorectal Cancer
-
Guardant Health (GH) receives coverage from UnitedHealthcare for Guardant360® CDx blood test as companion diagnostic in advanced lung and breast cancer
-
Guardant Health receives coverage from UnitedHealthcare for Guardant360® CDx blood test as companion diagnostic in advanced lung and breast cancer
-
Guardant Health (GH) and AnHeart Collaborate to Develop Guardant360 CDx and Guardant360 TissueNext
-
Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360® CDx and Guardant360 TissueNext™ as Companion Diagnostics for Taletrectinib in Advanced or Metastatic ROS1-Pos
-
Magistrate Judge Issues Favorable Recommendation Regarding Guardant Health’s Motion to Dismiss Lawsuit Brought by Illumina
-
Guardant Health to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
-
Guardant Health introduces Guardant GalaxyTM suite of advanced AI analytics to enhance its portfolio of cancer tests and accelerate biomarker discovery
-
Guardant Health (GH) Granted FDA Approval for Guardant360 CDx
-
Guardant Health receives FDA approval for Guardant360® CDx as companion diagnostic for Menarini Group’s ORSERDU™ for treatment of patients with ESR1 mutations in ER+, HER2- advanced or metastatic
-
Guardant Health and The Royal Marsden NHS Foundation Trust partner on highly anticipated TRACC Part C trial to use Guardant Reveal™ blood test to help guide treatment decisions in colorectal cancer
-
Guardant Health to showcase new data at ASCO GI 2023 demonstrating utility of its blood tests for patients with gastrointestinal cancers
-
Guardant Health to Participate in the 41st Annual J.P. Morgan Healthcare Conference
-
Guardant Health and Susan G. Komen® Partner to Develop Clinical Studies to Identify Early-Stage Breast Cancer Patients Who May Benefit From Additional Monitoring or Therapy
-
Guardant Health (GH) Reports Positive ECLIPSE Trial Results
-
Guardant Health announces positive results from pivotal ECLIPSE study evaluating a blood test for the detection of colorectal cancer
-
Guardant Health Announces Collaboration With AstraZeneca to Develop Companion Diagnostic to Identify Patients With ESR1-mutated Metastatic Breast Cancer
-
Guardant Health to Showcase New Data at San Antonio Breast Cancer Symposium 2022 Demonstrating Utility of Its Blood Tests for Advanced-stage Breast Cancer Patients
-
Guardant Health to Report Third Quarter 2022 Financial Results on November 3, 2022
-
Guardant Health Introduces GuardantINFINITY™ Smart Liquid Biopsy for Research Use to Help Bring New Cancer Therapies to Patients Sooner
-
Guardant Health to showcase new data at ESMO 2022 demonstrating utility of its portfolio of blood tests for advanced-stage cancer patients
-
Guardant Health Expands Strategic Collaboration With Merck KGaA, Darmstadt, Germany, to Help Accelerate Development of Precision Oncology Therapeutics
-
Guardant Health to Participate in the Morgan Stanley Global Healthcare Conference
-
Guardant Health Expands Use of Guardant Reveal™ Liquid Biopsy Test for Residual Disease Detection and Recurrence Monitoring to Include Early-Stage Breast and Lung Cancers
-
Guardant Health (GH) Receives FDA Approval for Guardant360 CDx as Companion Diagnostic for for ENHERTU
-
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for Daiichi Sankyo and AstraZeneca’s ENHERTU® for Treatment of NSCLC Patients With Activating HER2 Mutations
-
Guardant Health and Blueprint Medicines present real-world data identifying EGFR C797X mutation as most common resistance mechanism to osimertinib therapy at IASLC 2022 World Conference on Lung Cancer
-
Guardant Health (GH) Reports New Data from its Portfolio of Blood Tests and GuardantINFORM Platform
-
Guardant Health Announces New Data from its Portfolio of Blood Tests and GuardantINFORM™ Real-World Clinical-Genomic Platform at IASLC 2022 World Conference on Lung Cancer
-
Guardant Health (GH) Receives Medicare Coverage for Guardant Reveal Test
-
Guardant Health Receives Medicare Coverage for Guardant Reveal™ Test
-
Guardant Health to Report Second Quarter 2022 Financial Results on August 4, 2022
-
Guardant Health (GH) Announces Steve E. Krognes Joins Board of Directors
-
Steve E. Krognes Joins Guardant Health Board of Directors
-
Guardant Health (GH) and Adicon Partner to Offer Genomic Profiling Tests in China
-
Guardant Health and Adicon announce strategic partnership to offer comprehensive genomic profiling tests to accelerate development of new cancer therapies in China
-
Guardant Health Completes Purchase of Guardant Health AMEA Joint Venture
-
Guardant Health (GH) Adds Vijaya Gadde to Board
-
Guardant Health Appoints Vijaya Gadde to its Board of Directors
